Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registry

Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registry

Abstract Background Limited real‐world studies are available comparing infection risk between biologics for psoriasis. Objectives The primary aim was to determine the differential effect of currently available biologics on the risk of respiratory tract infections (RTI) among psoriasis patients in a...

Full description

Bibliographic Details
Main Authors: Lara S. van derSchoot, Hans J. M. M. Groenewoud, Marleen M. H. J. vanGelder, Marisol E. Otero, W. Peter Arnold, Maartje A. M. Berends, Marjolein S. De Bruin‐Weller, Sharon R. P. Dodemont, Marloes M. Kleinpenning, Marjolein I. A. Koetsier, Else N. Kop, John E. M. Körver, Astrid L. A. Kuijpers, Paula P. vanLümig, Johannes M. Mommers, Marcellus D. Njoo, Paul M. Ossenkoppele, Ron A. Tupker, M. Birgitte Visch, Lizelotte J. M. T. Weppner‐Parren, Elke M. G. J. deJong, Juul M. P. A. van denReek
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:JEADV Clinical Practice
Subjects:
biologics
COVID‐19
psoriasis
respiratory tract infections
serious infections
Online Access:https://doi.org/10.1002/jvc2.35

Similar Items

Similar Items